AD 177

Drug Profile

AD 177

Alternative Names: AD-177

Latest Information Update: 11 May 2005

Price : $50

At a glance

  • Originator Sosei R&D
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 11 May 2005 Discontinued - Preclinical for Psoriasis in United Kingdom (Transdermal)
  • 11 Dec 2002 This compound is still in active development
  • 04 Dec 2002 No development reported - Preclinical for Psoriasis in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top